title: Rationale and support for a One Health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings.
abstract: Although dog vaccination has been demonstrated to reduce and eliminate rabies in humans, during meetings there are often calls for further pilot studies. The assembled data proves that a widespread approach is now required. While zoonotic rabies has a minimal presence in developed nations, it is endemic throughout most of Asia and Africa, where it is considered to be a neglected tropical disease. In these areas, rabies causes an estimated annual mortality of at least 55,000 human deaths. Worldwide rabid dogs are the source of the vast majority of human rabies exposures. The World Health Organization (WHO), the Food and Agriculture Organization (FAO) of the United Nations and the World Organization for Animal Health (OIE) advocate a collaborative One Health approach involving human public health and veterinary agencies, with mass canine vaccination programs in endemic areas being the mainstay of strategies to eliminate dog-mediated human rabies. While post-exposure prophylaxis (PEP) is effective in preventing deaths in people exposed to rabies, it is comparatively expensive and has little impact on the canine reservoir that is the primary source of zoonotic rabies. Indiscriminate culling of the dog population is expensive and there is little evidence that it is effective in controlling rabies in non-island locations. Mass canine vaccination programs using a One Health framework that achieves a minimum 70% vaccination coverage during annual campaigns have proven to be cost-effective in controlling zoonotic rabies in endemic, resource-poor regions. Case studies, such as in Tanzania and Bhutan, illustrate how an approach based on mass canine rabies vaccination has effectively reduced both canine and human rabies to minimal levels. The multiple benefits of mass canine rabies vaccination in these cases included eliminating rabies in the domestic dog reservoirs, eliminating human rabies cases, and decreasing the rabies economic burden by reducing expenditures on PEP.
authors.affiliation: Merck Research Laboratories, Merck Animal Health, Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: Robert.Lavan@merck.com.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Lavan
authors.affiliation: Merck Animal Health, Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Alasdair I MacG
authors.initials: AI
authors.lastname: King
authors.affiliation: MSD UK, Milton Keynes, UK.
authors.forename: David J
authors.initials: DJ
authors.lastname: Sutton
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Kaan
authors.initials: K
authors.lastname: Tunceli
mesh_terms: D000818:Animals; D003362:Cost-Benefit Analysis; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D004285:Dogs; D019353:Endemic Diseases; D014943:Global Health; D006801:Humans; D032541:Mass Vaccination / Q000191:economics* / Q000379:methods; D000074823:One Health; D011818:Rabies / Q000453:epidemiology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage*; D015047:Zoonoses / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D011819:Rabies Vaccines
keywords: Canine; Immunoglobulin; One Health; Post-exposure prophylaxis; Rabies; Vaccination